Contact Us marketing@medicilon.com
CN
×
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button

ContainCBX-12Content

Mar 16,2021
PDC platform Cybrexa Therapeutics completes US$25 million in Series B financing
On March 10, 2021, Cybrexa Therapeutics, Inc., a biotech company focused on oncology, announced the completion of a $25 million Series B funding round to develop novel therapies through its Alphalex ™ Peptide Drug Conjutate (PDC) oncology targeting platform.
More
PDC platform Cybrexa Therapeutics completes US$25 million in Series B financing